Fundraising Fox
/Companies
Sign in

Clasp Therapeutics

Cambridge, US · Founded 2020 · 39 employees on LinkedIn · 7 known investors

Find your way into Clasp Therapeutics

Sign up to find every way you can get introduced to Clasp Therapeutics

  • Your email: who you already know at Clasp Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Clasp Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.

BiotechHealthtech

Investors · 7

Cure Ventureslisted by Cure VenturesBoston

How we know: funding news · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

BrightEdgereportedAtlanta

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Catalio Capital ManagementreportedNew York

How we know: a partner's Signal profile · funding news · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: funding news · Not right? Tell us

Third Rock VenturesreportedBoston · $100K – $5M

How we know: a partner's Signal profile · funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Clasp Therapeutics emerges with $150M based on work from Bert Vogelstein, Drew Pardoll — Clasp Txclasptx.com · Mar 2024Clasp Therapeutics Raises $150M in Fundingfinsmes.com · Mar 2024

Frequently asked questions

What does Clasp Therapeutics do?
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.
Who are Clasp Therapeutics's investors?
Clasp Therapeutics's investors include Catalio Capital Management, LP, Cure Ventures, Vivo Capital, BrightEdge, Catalio Capital Management, Novo Holdings, Third Rock Ventures.
Where is Clasp Therapeutics headquartered?
Clasp Therapeutics is headquartered in Cambridge, US.